ArticleThe British journal of dermatology2021
Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment.
Article in The British journal of dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Guideline
- Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review.JAMA dermatology · 2022Pooled it
- Implementation Science to Improve the Diagnosis and Management of Hidradenitis Suppurativa: HELyx Study Design Overview.Dermatology and therapy · 2025Article
- Review of Scoring Systems for Hidradenitis Suppurativa.Annals of dermatology · 2024Review
- Worst area local Hidradenitis suppurativa Activity and Severity Index-Revised (W-HASI-R): a study evaluating construct validity.The British journal of dermatology · 2023Article
- Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data.Frontiers in medicine · 2023Review
- International consensus definition of disease flare in hidradenitis suppurativa.The British journal of dermatology · 2022Article
- New treatments and new assessment instruments for Hidradenitis suppurativa.Experimental dermatology · 2022Review
- Incorporating Patient-Reported Outcomes as a Vital Sign for Dermatologic Clinical Care and Clinical Investigations.The Journal of investigative dermatology · 2022Article
- Self-Reported Hidradenitis Suppurativa Severity: Is It Useful for Clinical Practice?Dermatology and therapy · 2022Article
- International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting.Dermatology (Basel, Switzerland) · 2022Review
- A growing family of outcome measurement proposals for hidradenitis suppurativa.The British journal of dermatology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
backgroundValidated, reliable, globally accepted outcome measurement instruments for hidradenitis suppurativa (HS) are needed. Current tools to measure the physical signs domain for HS rely on lesion counts, which are time-consuming and unreliable.
objectivesTo assess the reliability and validity of the Hidradenitis suppurativa Area and Severity Index Revised (HASI-R) tool, a novel method for assessing HS severity, incorporating signs of inflammation and body surface area involved.
methodsThe measurement properties of the HASI-R tool were evaluated. The tool was created by combining the previously published HASI and Severity and Area Score for Hidradenitis instruments. Twenty raters evaluated 15 patients with HS in a hospital-based ambulatory dermatology clinic. The objectives of the study were to assess inter- and intra-rater reliability of the HASI-R and its components, as well as its construct and known-groups validity. Existing lesion count-based clinician-reported measures of HS and their components were also assessed. Raters were also asked their preferences regarding the various HS severity assessment tools.
resultsThe HASI-R had moderate inter-rater reliability [intra-class correlation coefficients (ICC) 0·60]. This was better than all other HS physical sign outcome measures evaluated, which had poor inter-rater reliability (ICC < 0·5). HASI-R had the highest intra-rater reliability (ICC 0·91). The HASI-R had good construct validity and demonstrated known-groups validity. The HASI-R was also the most preferred tool by all raters.
conclusionsResults from the clinometric assessment of the HASI-R are encouraging, and support continued evaluation of this clinician-reported outcome measure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.